The paper's citation list
No.The paper's citation list
1Cancer Immunotherapy: An Effective Tool in Cancer Control and Treatment. 2020;16:62 doi: 10.2174/1573394715666190913184853
2Neurologische Nebenwirkungen von Checkpoint-Inhibitoren. 2019;90:138 doi: 10.1007/s00115-018-0571-8
3Cell density quantification with TurboSPI: R2* mapping with compensation for off-resonance fat modulation. 2020;33:469 doi: 10.1007/s10334-019-00817-4
4Exploiting Cancer’s Tactics to Make Cancer a Manageable Chronic Disease. 2020;12:1649 doi: 10.3390/cancers12061649
5Immunotherapy. 2020;1244:255 doi: 10.1007/978-3-030-41008-7_13
6Strategies for Targeting Cancer Immunotherapy Through Modulation of the Tumor Microenvironment. 2020;6:29 doi: 10.1007/s40883-019-00113-6
7Mechanisms of the Antitumor Activity of Low Molecular Weight Heparins in Pancreatic Adenocarcinomas. 2020;12:432 doi: 10.3390/cancers12020432
8. 2020; doi: 10.1007/5584_2020_522
9Systems Medicine. 2021;593 doi: 10.1016/B978-0-12-801238-3.11605-8
10Bovine Dialyzable Leukocyte Extract IMMUNEPOTENT-CRP Induces Selective ROS-Dependent Apoptosis in T-Acute Lymphoblastic Leukemia Cell Lines. 2020;2020:1 doi: 10.1155/2020/1598503
11The emergence of drug resistance to targeted cancer therapies: Clinical evidence. 2019;47:100646 doi: 10.1016/j.drup.2019.100646
12Immunotherapy. 2018;995:131 doi: 10.1007/978-3-030-02505-2_6
13Immunotherapies and Combination Strategies for Immuno-Oncology. 2020;21:5009 doi: 10.3390/ijms21145009
14Novel Clinical Trial Designs and Statistical Methods in the Era of Precision Medicine. 2020;1 doi: 10.1080/19466315.2020.1814403
15Studying cancer immunotherapy using patient-derived xenografts (PDXs) in humanized mice. 2018;50: doi: 10.1038/s12276-018-0115-0
16Epithelial Ovarian Cancer and the Immune System: Biology, Interactions, Challenges and Potential Advances for Immunotherapy. 2020;9:2967 doi: 10.3390/jcm9092967
17Recent advances in localized immunotherapy of skin cancers. 2019;11:443 doi: 10.2217/imt-2018-0139
18Principles of Tumors. 2020;453 doi: 10.1016/B978-0-12-816920-9.00018-3
19CRISPR/Cas9 for Cancer Therapy: Hopes and Challenges. 2018;6:105 doi: 10.3390/biomedicines6040105
20Bioactive Nanoparticles for Cancer Immunotherapy. 2018;19:3877 doi: 10.3390/ijms19123877
21MPL nano-liposomal vaccine containing P5 HER2/neu-derived peptide pulsed PADRE as an effective vaccine in a mice TUBO model of breast cancer. 2019;303:223 doi: 10.1016/j.jconrel.2019.04.019
22Checkpoint inhibitors: What gastroenterologists need to know. 2018;24:5433 doi: 10.3748/wjg.v24.i48.5433
23Peptide-based targeting of immunosuppressive cells in cancer. 2020;5:92 doi: 10.1016/j.bioactmat.2020.01.006
24Exosomes Represent an Immune Suppressive T Cell Checkpoint in Human Chronic Inflammatory Microenvironments. 2020;1 doi: 10.1080/08820139.2020.1748047
25Prognostic and clinicopathological significance of PD-L1 overexpression in oral squamous cell carcinoma: A systematic review and comprehensive meta-analysis. 2020;106:104722 doi: 10.1016/j.oraloncology.2020.104722
26Editorial. 2019;12:3 doi: 10.1111/ors.12402
27Active immunotherapy of cancer: An overview of therapeutic vaccines. 2019;69:490 doi: 10.5937/arhfarm1906490F
28Combined strategies for tumor immunotherapy with nanoparticles. 2019;21:1441 doi: 10.1007/s12094-019-02081-3
29Biomaterials for Cancer Therapeutics. 2020;331 doi: 10.1016/B978-0-08-102983-1.00012-0
30Modeling immune cell behavior across scales in cancer. 2020;12:e1484 doi: 10.1002/wsbm.1484
31Immunotherapy for HER2-Positive Breast Cancer: Changing the Paradigm. 2019;11:248 doi: 10.1007/s12609-019-00332-4
32Immunostimulatory biomaterials to boost tumor immunogenicity. 2020; doi: 10.1039/D0BM01183E
33Review of PD-1/PD-L1 Inhibitors in Metastatic dMMR/MSI-H Colorectal Cancer. 2019;9: doi: 10.3389/fonc.2019.00396
34Cyto-Immuno-Therapy for Cancer: A Pathway Elicited by Tumor-Targeted, Cytotoxic Drug-Packaged Bacterially Derived Nanocells. 2020;37:354 doi: 10.1016/j.ccell.2020.02.001
35Immunotherapy and other systemic therapies for cutaneous SCC. 2019;99:104459 doi: 10.1016/j.oraloncology.2019.104459
36Durability of response in metastatic melanoma patients after combined treatment with radiation therapy and ipilimumab. 2020;7:7 doi: 10.2217/mmt-2019-0020
37O-acetylated Gangliosides as Targets for Cancer Immunotherapy. 2020;9:741 doi: 10.3390/cells9030741
38Evaluation of survival extrapolation in immuno-oncology using multiple pre-planned data cuts: learnings to aid in model selection. 2020;20: doi: 10.1186/s12874-020-00997-x
39Cancer and the Immune System: The History and Background of Immunotherapy. 2019;35:150923 doi: 10.1016/j.soncn.2019.08.002
40The need for rapid therapeutic efficacy testing for cancer therapy. 2020;113:104382 doi: 10.1016/j.yexmp.2020.104382
41Integrative Nanomedicine for New Therapies. 2020;321 doi: 10.1007/978-3-030-36260-7_12
42Emerging therapeutic agents for advanced non-small cell lung cancer. 2020;13: doi: 10.1186/s13045-020-00881-7
43The Resistance Mechanisms of Checkpoint Inhibitors in Solid Tumors. 2020;10:666 doi: 10.3390/biom10050666
44Molecular and Cell Biology of Cancer. 2019;117 doi: 10.1007/978-3-030-11812-9_7
45Novel therapeutic strategies for spinal osteosarcomas. 2020;64:83 doi: 10.1016/j.semcancer.2019.05.018
46The pint- sized powerhouse: Illuminating the mighty role of the gut microbiome in improving the outcome of anti- cancer therapy. 2020; doi: 10.1016/j.semcancer.2020.07.012
47Current Applications for Overcoming Resistance to Targeted Therapies. 2019;20:97 doi: 10.1007/978-3-030-21477-7_4
48Cancer: The Enemy from Within. 2020;223 doi: 10.1007/978-3-030-40651-6_9
49Th1 cytokines in conjunction with pharmacological Akt inhibition potentiate apoptosis of breast cancer cells in vitro and suppress tumor growth in vivo. 2020;11:2873 doi: 10.18632/oncotarget.27556
50Learning-accelerated discovery of immune-tumour interactions. 2019;4:747 doi: 10.1039/C9ME00036D
51Putting the Pieces Together: Completing the Mechanism of Action Jigsaw for Sipuleucel-T. 2020;112:562 doi: 10.1093/jnci/djaa021
52William B. Coley. 2020;47:413 doi: 10.1016/j.ucl.2020.07.001
53The Microbiome in Health and Disease. 2020;171:301 doi: 10.1016/bs.pmbts.2020.04.004
54Resistance to Targeted Therapies in Lymphomas. 2019;21:155 doi: 10.1007/978-3-030-24424-8_7
55A guide to cancer immunotherapy: from T cell basic science to clinical practice. 2020; doi: 10.1038/s41577-020-0306-5
56CRISPR/Cas9 technology: towards a new generation of improved CAR-T cells for anticancer therapies. 2020;19:191 doi: 10.1093/bfgp/elz039
57Current trends in cancer immunotherapy: a literature-mining analysis. 2020; doi: 10.1007/s00262-020-02630-8
58Overview of Current Immunotherapies Targeting Mutated KRAS Cancers. 2019;19:2158 doi: 10.2174/1568026619666190904163524
59Nanoparticles: Properties and Applications in Cancer Immunotherapy. 2019;25:1962 doi: 10.2174/1381612825666190708214240
60The Intriguing History of Cancer Immunotherapy. 2019;10: doi: 10.3389/fimmu.2019.02965
61Precision Medicine in Oncology. 2020;133 doi: 10.1002/9781119432487.ch5